Physician profile
Sara E Ackerman
NPI 1467504845
$6,320.16
in general payments reported to CMS, 2019-2025
37 companies · $981 in 2025
The $981 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,188 · 2022: $1,504 · 2023: $543 · 2024: $1,104 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,533.76 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,360.77 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,339.81 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $433.99 | 2021-2025 | |
| Genzyme Corporation | $427.96 | 2021-2022 | |
| Abbvie INC. | $361.97 | 2022-2025 | Vraylar |
| Regeneron Healthcare Solutions, INC. | $356.94 | 2021-2022 | |
| Lilly USA, LLC | $228.84 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $177.35 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $172.28 | 2024-2025 | Veozah |
| Grifols USA, LLC | $162.67 | 2021 | |
| Genentech USA, INC. | $154.88 | 2021-2022 | |
| Optinose US, INC. | $140.30 | 2021 | |
| Amgen INC. | $129.13 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.72 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $88.32 | 2023 | Seglentis |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.